Chinook Therapeutics, a biotech company creating targeted therapies for kidney diseases, raised an additional $106 million just before its planned merger with Aduro Biotech. Chinook said it will have at least $275 million in operating capital following the investment and merger. New investors include EcoR1 Capital, OrbiMed, funds managed by Rock Springs Capital, Avidity Partners, Surveyor Capital (a Citadel company), Ally Bridge Group, Monashee Investment Management LLC, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech.